Summary Polyclonal antibodies have been raised in rabbits to a haemocyanin adduct of a reductivelyactivated, fluorinated analogue of misonidazole. Fluorescence immunohistochemical studies show that the polyclonal antibodies bind to spheroid sections and tumour sections in patterns similar to those revealed by autoradiographic studies with a tritium-labelled derivative of the fluorinated misonidazole analogue.
The metabolic binding of nitroaromatic compounds to hypoxic cells (McCalla et al., 1970; Varghese et al., 1976; Miller et al., 1982) has been tested in both experimental (Chapman et al., 1981; Garrecht and Chapman, 1983; Franko, 1985; Hirst et al., 1985) and human tumours (Urtasun et al., 1986a, b) as an indicator of the presence of tumour hypoxia. It is possible that this information will be of use in tumour treatment design, whether it be in the application of radiosensitising strategies (Chapman, 1984; or of hypoxia-activated chemotherapeutic agents (Kennedy et al., 1980) . A number of approaches to the detection of 2-nitroimidazole adducts bound to macromolecules in hypoxic cells are under investigation including y-ray emission tomography (Jette et al., 1983; Rasey et al., 1985b; Wiebe et al., 1984) , autoradiography (Chapman et al., 1981; Urtasun et al., 1986a, b) and 19F magnetic resonance spectroscopy (MRS) (Raleigh et al., 1986 ). To our knowledge there are no reports of the use of fluorescence immunohistochemistry on tissue sections for this purpose. Although physically invasive, the technique would not require the use of radioactive tracers and ultimately might be applied to biopsy material. Initially, we chose to develop a histochemical assay based upon the hexafluorinated 2-nitroimidazole, CCI-103F (I), which is presently under investigation in connection with '9F MRS studies (Raleigh et al., 1986) . Polyclonal antibodies have been raised in rabbits to the protein adduct of reductively-activated CCI-103F and shown in fluorescence immunohistochemical studies to bind to spheroid and tumour sections in patterns similar to those revealed by autoradiographic studies of tritium-labelled CCI-103F.
Materials and methods

Chemicals
The synthesis of 1-(2-hydroxy-3-hexafluoroisopropoxypropyl)-2-nitroimidazole (CCI-103F, (I)) has been described previously (Raleigh et al., 1986) . Its tritium-labelled analogue ([3H]-CCI-103F) was synthesized in a manner analogous to that described for misonidazole (Born & Smith, 1983) Aliquots of 0.5 ml were stored at -17°C.
ELISA methodology
The sera were characterised by ELISA methods described previously including reagent dilution assay and competitive inhibition assay (Fuciarelli et al., 1985) . 9 .25MBqmg -1) was performed in the original growth flasks. For incubation in air, the drug was added in 0.2 ml medium to a final concentration of 0.10 mmol. dm -3. For incubation at low oxygen the flasks were flushed with N2 -5% CO2 for 1.5 h before the drug was added. This procedure results in an oxygen concentration equal to that in medium equilibrated with N2 -5% CO2 -0.13% 02 . Three hours after the drugs were added, the spheroids were rinsed several times with PBS and processed for autoradiography.
For incubation with non-radioactive CCI-103F in the fluorescence immunohistochemical studies, the spheroids were transferred with 20 mmol . dm-3 HEPES buffer (Gibco) to glass petri dishes containing 5.5 ml of Waymouth's medium. A separate growth flask was used for each of the two incubation conditions. The dishes were placed inside aluminium chambers fabricated with a removable base which forms a leakproof seal (via an 0-ring) upon reassembly. The chambers were degassed to an oxygen content (0.0005%) which is much lower than that achieved in spinner flasks.
The chambers were kept at 0°C during the degassing, then placed in a 37"C environmental chamber on a reciprocating table (1.1 Hz, 3cm travel) for 3.5 h. The dishes warmed to 37"C in 30 min. After incubation, the spheroids were rinsed several times in PBS and processed for histochemistry. Incubation in air under these conditions might alter the oxygen supply to the spheroids somewhat from that present in spinner flasks. However, this was not deemed an important factor in the qualitative comparison reported here for the results obtained with autoradiography and fluorescence immunohistochemistry. Ultimately, the chamber system (Franko et Autoradiography and grain scoring The spheroids were dehydrated, embedded in wax and sectioned at 4,pm. The slides were dipped in NTB-2 Nuclear Track Emulsion (Kodak) and exposed for 5 days. The emulsion was developed, fixed and dried, then the sections were stained with haematoxylin and eosin. The sections which passed through the centres of the spheroids were determined and these were used for scoring the grain density.
An ocular grid with 10,pm squares at an overall magnification of 1000 x was positioned along a spheroid radius perpendicular to the direction of sectioning (to minimise the effects of distortion resulting from compression during sectioning) and grains were recorded as a function of distance from the spheroid surface. The grain densities along 13 to 18 radii from nine different spheroids were averaged for each incubation condition.
Labelling of Walker 256 tumours with CCI-103F Walker 256 tumours were initiated by subcutaneous implantation of frozen stock in the flanks of Sprague Dawley rats. Ten days after implantation, a rat with two tumours 1.5 to 2.0cm in diameter was injected i.p. with 20mg of CCI-103F in 20ml of sterile saline, giving a whole body concentration of 200,pM. The tumours were excised 24h after the injection and fixed for 2 h in -20°C ethanol, then embedded in wax on the same day. Sections were obtained at 4 um and processed for immunohistochemistry following the procedures that were used for the spheroid sections. Histochemistry EMT6/Ed spheroids were fixed in -20°C ethanol (SainteMarie, 1962 ) and embedded in paraffin. Sections (2-4 pm) were deparaffinised, hydrated through an alcohol series and rinsed in PBS, pH 7.2, prior to overnight incubation at 4°C in rabbit anti-CCI-103F serum diluted 1: 50 in the same buffer. Following extensive rinsing in PBS, the sections were incubated for one hour at 37°C in rhodamine-conjugated, goat-antirabbit IgG (Cappel, Cooper Biomedical). Negative controls included substitution of the primary antibody with non-immune rabbit serum diluted 1:50 in PBS, or of the standard staining procedure of sections of multicellular spheroids which had not previously been incubated with CCI-103F. The tissue sections were rinsed and coverslipped with PBS-glycerol, 9:1 and observed with a Leitz Laborlux 12 microscope fitted with an HBO 5OW mercury burner and IVFI epifluorescence condenser. Rhodamine was visualised with an interference green filter combination BP 530-560 and RKP 580 beam splitter. Fluorescence microphotographs were made using equal exposure times for each experimental parameter, the time being dependent upon the objective lens and film speed.
Results
Reagent dilution assay A sample of antiserum from one of the rabbits was screened using the BSA-CCI-103F conjugate to coat the wells of the microtitre plates. A 1000-fold dilution of the conjugate containing 3.6mg ml-1 BSA-CCI-103F provided optimal absorption (Figure 1 ). Reducing the concentration of the BSA-CCI-103F conjugate in the coating buffer below 0.4 pg ml-1 significantly reduced the maximum ELISA value.
Wells coated with 0.4 mg ml -I BSA showed a slight non- specific cross-reactivity with the antiserum which could be blocked with very low concentrations of BSA test solutions in the wells of the microtitre plate. The titre of the antiserum was 10-5and did not change after repeated immunisation of the rabbits. A 50% positive response occurred at a 104-fold dilution of antiserum and competitive inhibition studies were performed at this dilution.
Specificity of the antiserum
Although the exact nature of the adduct of reductivelyactivated CCI-103F with proteins and other cellular molecules is not known, a series of chemicals was tested for ability to inhibit the binding of the antiserum to BSA-CCI-103F conjugate which was immobilised by adsorption to the surface of the wells in the microtitre plate. Competition for the anti-haemocyanin-CCI-103F antibodies was most efficient with CCI-103F itself (Figure 2 ). The fact that none of imidazole, 2-nitroimidazole, misonidazole, nor D,Lhistidine showed a strong interaction with the antiserum indicates that the fluorinated side-chain of CCI-103F is the major antigenic determinant. The weak inhibitory effect of hexafluoroisopropanol indicates that the epitope includes more of the side chain than the terminal hexafluoroisopropoxy group in CCI-103F.
Fluorescence immunohistochemistry
Sections of spheroids which had been incubated with CCI-103F in the absence of oxygen showed a uniform fluorescence intensity from the surface of the spheroid inward to the edge of the necrotic centre (Figure 3a) . For spheroids incubated in air-saturated medium containing CCI-103F, the fluorescence intensity which increases over the first 100-150,pm of the periphery, achieved maximum intensity near the inner edge of the rim of viable cells (Figure 3b) . These patterns are similar to the patterns of binding revealed in autoradiographic studies of adducts formed between cellular molecules and [14C]-or [3H]-misonidazole (Franko, 1985; or with [3H]-CCI-103F (see below). This is consistent with an ability of the fluorescence immunohistochemical assay to discriminate between aerated and hypoxic cells. The fraction of cells in EMT6/Ed spheroids which is radiobiologically hypoxic has been shown to be -20% (Franko & Koch, 1983) .
The fluorescence immunohistochemical assay is qualitative at this stage, but it is possible to define its ability to discriminate between oxygenated and hypoxic cells by reference to autoradiographic studies of [3H]-CCI-103F bound to spheroids labelled in air or in the absence of oxygen. The patterns of fluorescence in the spheroid sections ( . This is because the more hydrophobic CCI-103F (Raleigh et al., 1986 ) binds more avidly to aerated cells than does misonidazole. Nevertheless, CCI-103F binding can discriminate between these two types of cells almost as well as can misonidazole. Figure 3c is a haematoxylin-eosin-stained section of Walker 256 carcinoma labelled in vivo with CCI-103F as described in Materials and methods. In the centre of the field a zone of relatively healthy cells is evident which is bounded on three sides by necrotic cells and cellular debris. An adjacent tissue section, immunohistochemically stained for the hypoxic marker ( Figure 3d ) reveals positive staining of the zone of necrotic cells and several layers of healthy cells adjacent to the necrotic regions. The fluorescent labelling of areas bordering necrotic regions was observed consistently throughout the tumour tissue sections.
Discussion
Recent success in the use of non-invasive 19F magnetic resonance spectroscopy to detect the binding of fluorinated 2-nitroimidazoles to tumour hypoxia in vivo (Raleigh et al., 1986 ; and in preparation) has led to an interest in developing an ancillary, non-radioactive histochemical assay for hypoxia. It was known that the side chain of a substituted 2-nitroimidazole is efficiently bound to hypoxic cells Rasey et al., 1985a) Liu, 1984; McClelland et al., 1984 McClelland et al., , 1985 . In vitro studies Rasey et al., 1985a) appear to confirm the idea that the binding agent is a molecular product incorporating both ring and side chain of reductively-activated 2-nitroimidazoles. At present, the evidence favours an hydroxylamine derivative (II) as the binding agent (Varghese, 1983; McClelland et al., 1984 McClelland et al., , 1985 . The hydroxylamine intermediate is stabilised to hydrolytic decomposition at pH values less than 4 (McClelland et al., 1984) . This, combined with the knowledge that proteins are major sites of binding in hypoxic cells (Miller et al., 1982; Smith, 1984) (Varghese, 1983; Smith & Born, 1984) . The successful development of a fluorescence immunohistochemical detection for CCI-103F opens the possibility that the present approach may be useful in raising antibodies to 2-nitroimidazoles with a variety of side-chains. The hydrolytic instability of the hydroxylamine intermediate at neutral pH (McClelland et al., 1984) may account for the limited diffusion of the binding agent away from the hypoxic cells Chapman et al., 1983;  Franko . This is an essential property of hypoxia markers based on the reductive metabolism of (Figure 4) indicates that the binding intermediate formed from each has similar diffusion properties, even though the side-chain differs markedly in polarity. Nevertheless, in some cases, the side chain does affect the efficiency of reductive binding of 2-nitroimidazoles to both cells and nucleic acids (Silver et al., 1986) . These distinctions may ultimately be important to hypoxia marker development.
The fluorescent labelling pattern observed in oxygenated and hypoxic spheroids is consistent with the pattern previously demonstrated by autoradiography (Figure 4 and Franko et al., 1982 Franko, 1985 . The labelling pattern of cells adjacent to necrotic regions in the Walker 256 carcinoma is consistent with the hypoxic fraction of 7% reported for this tumour (Clement et al., 1978) , and is encouraging regarding the utility of the immunohistochemical approach to detect hypoxia in vivo. The amount of CCI-103F used to label the tumour in vivo produced no obvious long term toxicity although a transient depressive effect was noted. Lower whole body concentrations over longer exposure times, which was achieved by repeated injections, also produced binding of CCI-103F to hypoxic cells in tumours but no obvious long term toxicity (Raleigh et al., 1986) . A much more detailed study of CCI-103F toxicity is required, however, before its clinical application is considered.
The long range goal of our research is to develop a physically non-invasive method of measuring hypoxia in human tumours. We believe that 19F MRS offers some potential in this regard (Raleigh et al., 1986; and in preparation) and are studying a selection of fluorinated 2-nitroimidazoles as potential markers. The availability of a correlative assay during the development stages of the 19F MRS approach is viewed as essential. To 
